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Interferon lambda (IFN-λ) is an antiviral naturally produced in response to viral infections,
with activity on cells of epithelial origin and located in the mucosal surfaces. This
localized activity results in reduced toxicity compared to type I IFNs, whose receptors
are ubiquitously expressed. IFN-λ has been effective in the therapy of respiratory viral
infections, playing a crucial role in potentiating adaptive immune responses that initiate
at mucosal surfaces. Human IFN-λ has polymorphisms that may cause differences
in the interaction with the specific receptor in the human population. Interestingly,
bovine IFN-λ3 has an in silico-predicted higher affinity for the human receptor than
its human counterparts, with high identity with different human IFN-λ variants, making
it a suitable antiviral therapeutic candidate for human health. Here, we demonstrate
that a recombinant bovine IFN-λ (rbIFN-λ) produced in HEK-293 cells is effective in
preventing SARS-CoV-2 infection of VERO cells, with an inhibitory concentration 50%
(IC50) between 30 and 50 times lower than that of human type I IFN tested here (α2b and
β1a). We also demonstrated the absence of toxicity of rbIFN-λ in human PBMCs and the
lack of proinflammatory activity on these cells. Altogether, our results show that rbIFN-λ is
as an effective antiviral potentially suitable for COVID-19 therapy. Among other potential
applications, rbIFN-λ could be useful to preclude virus dispersion to the lungs and/or to
reduce transmission from infected people. Moreover, and due to the non-specific activity
of this IFN, it can be potentially effective against other respiratory viruses that may be
circulating together with SARS-CoV-2.
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INTRODUCTION
Interferons (IFNs) are antiviral cytokines produced by almost any cell type upon recognition of
viral molecular patterns and constitute the first line of defense against viral infections. Two types
of IFNs are produced during the innate phase of the immune response: type I IFNs (13 subtypes of
IFN-α, IFN-β, IFN-ε, IFN-k, and IFN-ω in humans) and type III IFNs (4 subtypes: IFN-λ1 or IL-29,
IFN-λ2 or IL-28A, IFN-λ3 or IL-28B, and IFN-λ4 in humans) (1). These IFNs bind to specific
receptors on target cells and initiate similar but non-redundant signaling pathways that lead to the
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expression of IFN-stimulated genes (ISGs) (2, 3). Proteins
produced from those ISGs trigger an anti-viral state in the target
cells that directly interfere with different steps of viral replication
and indirectly modulate the host-immune response to virus
infection (4–7). Due to their biological activity, IFNs have been
studied or tested as therapeutic tools in the treatment of emerging
and reemerging coronaviruses and other viral infections for
which no approved drugs or vaccines are available (8–11).
The main difference between both IFN types is the location
of their receptors. Type I IFNs recognize specific receptors that
are ubiquitously expressed on the surface of all nucleated cells.
Consequently, the clinical use of these molecules frequently
causes side effects including fever, fatigue, and malaise mainly
due to systemic proinflammation elicited on non-target cells
(12, 13). Conversely, IFN-λ signals through the engagement of a
heterodimeric receptor complex IFNLR1/IL10Rβ (IFNLR) whose
expression is restricted to cells and tissues of epithelial origin,
including epithelial cells of the respiratory and digestive tracts
(1, 14). Due to the IFNLR location, IFN-λ constitutes the first
line of defense controlling virus infection at the site of entry.
The COVID-19 pandemic has led to reconsider the use of
available antivirals, and among them, IFNs. The use of IFNs is
supported by the fact that SARS-CoV-2 induces a very weak
endogenous expression of IFNs in infected cells (15–17) that
may hamper the early innate immune response after infection.
Hence, the use of exogenous IFNs, either for prophylaxis or early
therapy to stimulate antiviral immunity, might be successful for
treating COVID-19 (18, 19). In this context, IFN-λ has arisen as
a promising candidate due to its localized activity on epithelial
cells of the respiratory tract, which may reduce side effects and
inflammation associated with the systemic action of type I IFNs.
One of the limitations of using human IFN-λ as a universal
therapeutic molecule resides in the fact that it has several genetic
variants (20, 21) that might have different stability and affinity in
the interaction with the IFNLR. Engineering of IFN-λ to assess
natural or in silico predicted mutations critical to maintaining
the antiviral activity proved that the strength of the interaction
of between IFN-λ and its receptor could modulate downstream
functions (22–26). The strength of this interaction may modify
the expression of the ISGs involved in the response to SARS-
CoV-2 infection and even the virus receptor (ACE 2) on epithelial
cells (27), promoting the reduced IFN signaling in infected cells.
Seeking for an innovative high-performance low-cost IFN-λ for
use in human health therapy, we developed a recombinant bovine
IFN-λ expressed in HEK-293 cells (rbIFN-λ) hypothesizing
that an enhanced binding capacity to the human heterodimeric
receptor complex will improve its antiviral efficacy.
We have recently demonstrated that rbIFN-λ can activate the
humanMx-promoter and that it has an effective antiviral activity
in vitro against vesicular stomatitis virus (VSV), foot-and-mouth
disease virus (FMDV), and bovine viral diarrhea virus (BVDV)
(28). Moreover, treatment of calves with rbIFN-λ protected these
animals from the disease caused by BVDV, downregulated the
proinflammatory response, and promoted the development of
the adaptive immune response (29). Here, we assessed for the
first time the antiviral activity of this rbIFN-λ against SARS-
CoV-2 in vitro and its safety on human immune cells. The
affinity of bIFN-λ for the human receptor was also analyzed and




HEK-293 cells were provided by the Argentinean Cell Bank at
INTA and VERO-E6 cells by the Servicio Cultivos Celulares,
INEI-ANLIS “Dr. Carlos G. Malbrán.” MDBK-t2 cells (30)
were kindly provided by Dr. Bryan Charleston (The Pirbright
Institute). Cell lines were maintained in Earle’s Minimum
Essential Medium (EMEM) containing 10% fetal bovine serum
(FBS; Internegocios, Argentina), 2mM L-glutamine, 1mM
sodium pyruvate, 1,500 mg/L sodium bicarbonate, 15mM
HEPES, and a commercial solution containing streptomycin
(10µg/ml), amphotericin B (0.025µg/ml), and penicillin (10
UI/ml) at 37◦C, 5% CO2. VERO cells cannot produce IFNs, but
can respond to exogenous treatment (31).
Peripheral blood mononuclear cells (PBMCs) were purified
from heparinized blood from two different volunteers using
Histopaque R© 1083 (Sigma-Aldrich, Thermo Fisher, DE USA)
centrifuged at 1,000 × g for 30min. A written informed
consent was obtained from each peripheral blood donor, and
procedures were in accordance with the 1964 Declaration of
Helsinki and its later amendments and approved by National
Ethics Committee of Buenos Aires Province through ACTA-
2020-16644926-GBEBA-CECMSALGP.
A local strain of SARS-CoV-2 isolated from a clinical sample
positive for COVID-19 in Buenos Aires, Argentina was used in
this study. This strain was in vitro characterized by staff of the
“Servicio Virosis Respiratorias INEI-ANLIS-Malbrán,” verifying
its cytopathic effect (CPE) on VERO cells. Its whole genome was
also sequenced (GISAID accession numbers EPI_ISL_420600).
Viral stock was produced by infecting VERO cells and titrated
following standard procedures. Briefly, serial 10-fold dilutions
of the viral stock were plated in sextuplicate, and after 48–
72 h of incubation at 37◦C, the number of wells showing CPE
was recorded. Viral titers were estimated using the Reed and
Müench method and expressed in tissue culture infective dose
50% (TCID50)/ml (32).
Recombinant Bovine IFN-λ
Details of sequence, cloning, and expression of the rbIFN-λ
(bovine IFN-λ3, GenBank accession number HQ317919.1) have
already been published (28). The batch used in this study was
produced in HEK-293 cells and quantified in a reporter system
using MDBK-t2 cells stably transfected with a construct that
contains the human promoter of the MxA gene upstream of a
reporter gene, chloramphenicol acetyltransferase enzyme (CAT)
(30). Units of biologically active bovine rIFN-λ were measured
by MxA-CAT ELISA as previously described (33) with some
modifications. Briefly, MDBK-t2 cells were seeded into 12-well
tissue culture plates at a density of 5 × 105 cells/well. After
24 h of incubation at 37◦C and 5% CO2, the culture medium
was replaced with 500 µl of medium containing 250 µl of
different dilutions of the rbIFN-λ preparation. Following a 24-h
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incubation, cells were washed with cold PBS 1×, lysed for 20min
in lysis buffer, and CAT expression was determined from the
cell extracts by CAT ELISA kit (Roche Applied Sciences, IN,
USA) following themanufacturer’s instructions. Units of antiviral
activity per milliliter of the samples were calculated from a
standard curve using recombinant bovine IFN-α (from 0.3 to 5.0
IU/ml). The batch produced for this study contained 45 IU/ml of
active rbIFN-λ. Recombinant human interferons (rhIFNs) α2b
and β1a were kindly provided by Biosidus S.A. (Buenos Aires,
Argentina) and contained 3 and 24× 106 IU/ml, respectively.
In silico Analyses: Modeling and Docking
The sequences of bovine IFN-λ3 and human IFN-λ1, 2, 3, and
4 were retrieved from the GenBank and aligned for identity and
similarity, identifying conserved critical regions (34).
Two different in silico approaches were used to predict the
affinity of bIFN-λ for the human receptor. Using the crystallized
ternary complex (hIFN-λ3/IFNLR) structure (PDB accession
number 5T5W), a protein structural modeling was performed
based on the amino acid sequences of human IFN-λ1, 2,
and 3 and bovine IFN-λ3 (SWISS MODEL software; https://
swissmodel.expasy.org/). This modeling allowed us to visualize
the predicted interaction in the receptor pocket. Each IFN-λ
variant was guided by distance restrictions between the Cα atom
in contact between the ligand and the receptor and docked into
either the structure of IFNLR1/IL10Rβ receptor or the IFNLR1
monomer alone (from PDB) using HDOCK server (http://
hdock.phys.hust.edu.cn). After the docking was completed, we
identified the 10 structures that yielded the lowest docking free
energy for each IFN-λ and selected the one with the lowest
root-mean-square deviation (RMSD) against the natural ligand.
UCSF Chimera software was used to visualize the models. The
dissociation constant (Kd) and free Gibbs energy of binding
(1Gbind) were then estimated (Prodigy server https://bianca.
science.uu.nl//prodigy/).
Using the hIFN-λ3/IFNLR complex structure, the interface
residues between hIFN-λ3 and each subunit of the heterodimeric
receptor were determined using PDB SUM database (35).
This crystallographic structure (5T5W) is already an IFN-
λ3 mutant (mut-hIFN-λ3) conceived to improve the binding
affinity for its receptor (Mendoza 2017). Mutation on the
interface residues of the mut-hIFN-λ3 was incorporated using
FoldX software (Schymkowitz 2005), creating new variants with
replaced interface residues present in hIFN-λ3 or bIFN-λ3, and
the 1Gbind of the interaction of the ligand–receptor complex
was estimated. Mutant structures were visualized using VMD
software (36).
Viability Assessment
The metabolic activity of VERO cells and PBMCs pretreated with
4.5, 9, and 18 IU/ml of rbIFN-λ was measured with TACS R©
XTT Cell proliferation Assay Kit (TREVIGEN, Gaithersburg,
MD, USA) according to the manufacturer’s instruction and
as previously reported (37). OD values for mock-treated cells
were computed as reference of viable cells. Control dead cells
were obtained by performing an osmotic shock, incubating the
cells overnight (ON) with PBS. Percentage of living cells was
referred to values of untreated control wells. Samples were run
in triplicate.
PBMCs were also stained with a LIVE/DEADTM Fixable Dead
Cell Stain Kit (Thermo Fisher), according to the manufacturer’s
recommendations. Fluorescence intensity was determined by
FACS analysis at 665 nm (BD Biosciences FACSCaliburTM), and
results were analyzed using a specific software (FlowJo V10; BD,
OR USA).
Cytokine Responses
Heparinized whole blood samples from two different donors
were incubated at 37◦C and 5% CO2 with LPS (20 ng/ml, Sigma
Aldrich–Thermo Fisher); rbIFN-λ (5 IU/ml) or both rbIFN-λ
and LPS were mock treated. After 24 h of incubation, plasma
samples were separated by centrifugation (1,200× g, 10min) and
tested for IL-6 and IL-10 production by a chemiluminescent assay
at a private clinical laboratory (IACA Laboratorios, Argentina).
Antiviral Activity Against SARS-CoV-2
VERO cells were seeded into 96-well tissue culture plates
(1.5 × 104 cells per well) 24 h prior to treatment with serial
dilutions (0.0175 to 18 IU/ml) of rbIFN-λ and recombinant
human IFN-α2b and IFN-β1a (rIFN-α and rIFN-β, respectively),
kindly provided by Biosidus SA. (Argentina), as control
treatments. After an ON incubation, the supernatants were
removed and cells were infected with SARS-CoV-2 at a MOI
of 0.5 in infection medium (as it was previously described
but containing only 2% FBS) for 1 h. Medium containing the
inoculum was removed and replaced with 200µl per well of fresh
medium (2% FBS) supplemented with the corresponding rIFN
at the indicated concentrations or medium alone. Plates were
incubated for 48 h, when infected cell control wells showed CPE.
At this time point, cell supernatants were collected, pelleted for
10min at 6,000 × g to remove debris, and then transferred to
sterile collection tubes for RNA extraction. The cell monolayers
were stained with crystal violet, and the resulting OD read
at 575 nm in a microplate reader (Synergy H1, BioTek, USA).
These results were used to calculate the corresponding IFN
concentration that provided 50% of protection to the infection of
the cells in culture (inhibitory concentration 50, IC50). Triplicate
wells containing IFN-treated non-infected cells were run in
parallel as toxicity controls in every experiment.
Detection of SARS-CoV-2 Using a TaqMan
qRT-PCR Assay
The antiviral activity of the rbIFN-λ in VERO cells with
the SARS-CoV-2 was also assessed by detecting viral genome
in cell culture supernatants through an optimized qRT-PCR
assay. Briefly, 140 µl of cell culture supernatants seeded in
quadruplicates was processed to extract total RNA using the
QIAamp Viral RNA Mini Kit (Qiagen, Germany). Reverse
transcription and amplification of SARS-CoV-2 E-gene were
performed using the Lightmix Modular SARS-CoV (COVID-19)
(TIB MOLBIOL-Roche, Switzerland) and the SuperscriptTM III
Platinum OneStep qRT-PCR kits (Invitrogen, Thermo Fisher)
and run on an ABI 7500 Real-Time PCR System (Applied
BioSystems, Thermo Fisher) following standard procedures.
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Reverse transcription was done at 50◦C for 10min, followed by
a polymerase activation and target denaturation step at 95◦C
for 10min, and PCR amplification was run at 95◦C for 15 s and
58◦C for 35 s (45 cycles). All reactions were performed in a final
volume of 25 µl, containing 5 µl of total RNA. A reference
curve built upon serial dilutions ranging from 6 × 10−1 to 6
× 106 copies/µl was used to calculate the number of genome
copies in each sample, using standards provided by the Pan
American Health Organization (SARS-like Wuhan, Iv-RNA E
gene standard 1× 108 copies/µl and SARS-like Wuhan, Iv-RNA
RdRP gene standard, 1 × 108 copies/µl). The reduction of the
number of SARS-CoV-2 genome copies was also used to estimate
IC50, as described for the cell monolayer staining method.
As for the previous section, all experiments involving infective
SARS-CoV-2 were performed by the staff of the “Servicio Virosis
Respiratorias INEI–ANLIS Dr. Carlos G. Malbrán” at the ANLIS
“Dr. Carlos G. Malbrán” BSL-3 facilities.
Statistical Analysis
The standard curve used to estimate viral RNA quantities
was run in triplicate and analyzed using GraphPad Prism 9.
Results obtained for antiviral activity against the different
IFN concentrations were compared using one-way ANOVA
Kruskal–Wallis test, followed by Dunn’s multiple comparison
test. Normal distribution of these values was previously
confirmed using the D’Agostino-Pearson normality test
(GraphPad Prism 9). The confidence interval used was 95% or
99% depending on the experiment.
RESULTS
Interaction of rbIFN-λ With Human
Receptors
There are four human IFN-λ coding sequences clustered at
chromosome 9: IFN-λ1 (IL29), IFN-λ2 (IL28A), IFN-λ3 (IL28B),
and IFN-λ4. Identity between the amino acid sequences of
human IFN-λ was first analyzed (Table 1A). The highest degree
of identity was found between human IFN-λ3 and IFN-λ2
(96%), followed by the comparison to IFN-λ1 (80%). Identity
between human IFN-λ1 and λ2 was 71%, while IFN-λ4 was very
different to all the other human IFN-λ (identities <30%). We
then compared human IFN-λ1 to IFN-λ4 with the sequence of
the rbIFN-λ. Interestingly, the percentage of identical residues
were equivalent when compared to human IFN-λ1, 2, and
3 sequences (between 64 and 68%) as well as the similarity
that ranged between 74 and 75% (Table 1B). As expected from
the comparison among human IFN-λ, both the identity and
similarity between the rbIFN-λ and hIFN-λ4 were much lower
(30 and 43%, respectively). Due to its differences with the other
IFN-λ variants under study (both human and bovine), the
hIFN-λ4 was excluded from further analysis.
To the best of our knowledge, the potential antiviral activity
of bovine IFN-λ on human cells has never been assessed. An in
silico analysis was first performed to predict the tridimensional
structure of the interaction between the bIFN-λ and the human
receptor (IFNLR). A protein structure was modeled using the
amino acid sequences of the bIFN-λ and the hIFN-λ1, 2,
TABLE 1 | Analysis of bovine and human IFN-λ sequences.
hIFN-λ2 hIFN-λ3 hIFN-λ4
A. Identity between human IFN-λ
hIFN-λ1 139/196 (71%) 153/189 (80%) 54/190 (28%)
hIFN-λ2 – 188/196 (96%) 44/171 (26%)
hIFN-λ3 – – 45/175 (26%)
Identities Similarities Expect
B. Identity and similarity between bovine and human IFN-λ
hIFN-λ1 111/174 (64%) 131/174 (75%) 5e−74
hIFN-λ2 131/198 (66%) 148/198 (74%) 8e−84
hIFN-λ3 134/198 (68%) 149/198 (75%) 2e−86
hIFN-λ4 48/160 (30%) 70/160 (43%) 4e−11
(A) Identity of the amino acid sequences between human IFN-λ1 and human IFN-λ4. (B)
Identities, positives (similarity), and E-values of the alignments between human IFN-λ1
and human IFN-λ4 and the rbIFN-λ sequence.
TABLE 2 | Interaction with the human IFNLR.
Docking 1Gbind (kcal/mol) Kd










(A) The interaction between IFNLR and each modeled IFN-λ was studied in terms of
stability through a docking assessment. The free Gibbs energy of binding (1Gbind ) and the
dissociation constant (Kd ) were computationally estimated. (B) An in silico mutagenesis
analysis was performed using FoldX software by replacing the interface residues present
in both the wild-type hIFN-λ3 and in bIFN-λ. The free Gibbs energy of binding (1Gbind )
of the interaction of the ligand–receptor complex is depicted. hIFN-λ1–3: human IFN-λ1
to 3; bIFN-λ: bovine IFN-λ; WT hIFN-λ3: wild-type human IFN-λ3; mut-hIFN-λ3: mutant
human IFN-λ3; IFNLR: human IFN-λ receptor.
and 3, and the crystal structure of the human IFN-λ3/IFNLR
complex was used as template. With these models, PDB files
were generated and run in a docking software to visualize the
predicted interaction in the receptor pocket, where IFN-λ binds
to trigger the JAK/STAT pathway. Both human and bovine
IFN-λ exhibited similar secondary and tertiary structures, thus
suggesting that they may interact similarly with the IFNLR
(Supplementary File 1).
The interaction between IFNLR and each modeled IFN-λ
was studied in terms of stability through a docking assessment.
The free 1Gbind and the Kd for the best model generated by
the docking procedure were computationally estimated. As it
is shown in Table 2A, the bovine IFN-λ3/IFNLR prediction
yielded the lowest1Gbind andKd values, suggesting amore stable
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interaction between the bIFN-λ and the IFNLR compared to the
human IFN-λ. The highest binding stability of bovine IFN-λ
was also observed in the interaction with the monomer IFN-λR1
(data not shown).
Based on the crystallographic structure of the hIFN-λ3/IFNLR
complex, interface residues were identified (Figure 1). Some of
them had been mutagenized previously to obtain the crystal
structure (25). The impact of these residues present in both
wild-type human and bovine IFN-λ3 on the stability of the
interaction with IFNLR was assessed by an in silico mutagenesis
analysis. These interface residues present in the mut-hIFN-λ3
were replaced by the bovine and wild-type IFN-λ3 amino acids
and fitted within the hIFN-λ3/IFNLR structure. The 1Gbind
of the interaction was determined (Table 2B). The mutations
performed on the PDB structure of mut-hIFN-λ3 were H95N,
R15Q, H91L, D87E, and D73E (Figure 1, center), and K24R,
F146L, A150T, and N154 (Figure 1, right), based on the amino
acid residues present in bIFN-λ. According to 1Gbind values,
bovine IFN-λ3 showed higher affinity for the IFNLR than
human wild-type IFN-λ3, and the interface amino acids of
the bovine sequence may be responsible for this increased
interaction efficacy.
Safety of rbIFN-λ
In order to be used as a human therapeutic agent, rbIFN-
λ must be safe for human cells and unable to upregulate
proinflammatory cytokines in immune cells.
In a first experiment, PBMCs from two different healthy
donors were incubated ON with 4.5, 9, or 18 IU/ml of rbIFN-
λ, stained with a specific marker to differentiate between live and
dead cells and analyzed by FACS (Supplementary File 2). Viable
and dead cells were quantified as a whole and by gating events
according to their size and granularity to identify lymphocytes,
granulocytes, and monocytes. No differences were recorded in
the number of dead and live cells associated to the increasing
concentrations of rbIFN-λ assessed. Mortality rate yielded values
below 1% for all samples, even when 18 IU/ml of rbIFN-λ








A. Percentage of dead cells
DONOR 1 0.82 ± 0.11 1.01 ± 0.99 0.74 ± 0.37 0.72 ± 0.38
DONOR 2 0.58 ± 0.29 0.41 ± 0.08 0.98 ± 0.55 0.90 ± 0.42
B. Percentage of total cells
Donor 1 Granulocytes 24.5 ± 0.92 26.4 ± 1.62 26.4 ± 0.62 24.0 ± 1.93
Monocytes 4.66 ± 0.15 5.56 ± 0.51 5.32 ± 0.64 4.82 ± 0.10
Lymphocytes 58.4 ± 1.45 53.0 ± 1.07 56.0 ± 2.83 57.7 ± 2.06
Donor 2 Granulocytes 43.9 ± 1.9 45.5 ± 1.6 42.3 ± 1.9 41.5 ± 3.6
Monocytes 3.70 ± 0.99 3.57 ± 1.2 4.16 ± 1.1 2.86 ± 0.8
Lymphocytes 44.8 ± 1.70 41.9 ± 0.96 41.7 ± 4.8 42.4 ± 5.57
Leucocytes were purified from heparinized blood from two healthy volunteers and treated
(or mock-treated) with increasing concentrations of bovine rIFN-λ (4.5; 9; and 18 IU/ml).
After ON incubation, cells were stained with LIVE/DEADTM Fixable Dead Cell Stain Kit and
analyzed by FACS. (A) Lymphocytes were gated based on the morphological criteria (SSC
vs. FSC cytogram), and the percentage of dead cells after each treatment was estimated.
(B) Lymphocytes, monocytes, and granulocytes were gated based on the morphological
criteria (SSC vs. FSC cytogram), and the percentage of total cells within each cell type was
estimated and compared between treatments. Mean values ± SD from triplicate samples
are depicted for each treatment.
FIGURE 1 | Crystallographic structure of hIFN-λ and hIFN-λ/IFNLR in silico-mutated complex. Based on the crystallographic structure of the hIFN-λ3/IFNLR complex
(PDB: 5T5W), IFN-λ residues in the interface with IFNLR were replaced with those present in the bovine interface using FoldX software. All residues in the IFN-λ
interface are colored purple and blue, and mutated residues (in blue) are indicated. Left: mutated structure of the hIFN-λ/IFNLR1/IL10Rβ complex; side faces of
mutated hIFN-λ interacting with IFNLR1 (center) and IL10Rβ (right).
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FIGURE 2 | Effect of the bovine rIFN-λ on the viability of VERO cells and
human PBMCs. VERO cells (A) and PBMCs (B) were treated with 4.5, 9, and
18 IU/ml of recombinant bovine IFN-λ (rbIFN-λ) for 18 h and their capacity to
reduce XTT was assessed. Control cell samples were also incubated ON with
PBS to induce an osmotic shock (OS). Percentage of living cells was referred
to values of mock-treated controls. Mean values ± SD from triplicate samples
are depicted for each dilution for each experiment (EXP.) or human donor.
were used, and not different to those found in the mock-treated
cells (Table 3A). Likewise, no changes in cell size or granularity
were found after rbIFN-λ treatment, and the percentage of
granulocytes, monocytes, and lymphocytes were almost identical
between mock and rbIFN-λ treatments (Table 3B).
Safety of rbIFN-λ was then assessed by measuring the
metabolic activity of VERO cells (Figure 2A) and human PBMCs
(Figure 2B) after anON incubationwith the same concentrations
TABLE 4 | Effect of the bovine rIFN-λ on the induction of inflammatory responses
in human immune cells.
Treatment
Mock LPS rbIFN-λ LPS + rbIFN-λ
Donor 1 IL-6 <2 >10,000 1,650 >10,000
IL-10 <5 >1,000 22.2 391
Donor 2 IL-6 <2 >10,000 270 >10,000
IL-10 <5 757 <5 117
Whole blood samples were stimulated ON with LPS (20 ng/ml), rbIFN-λ (18 IU/ml), a
combination of both, or mock-treated with dilution buffer (PBS). IL-6 and IL-10 were
quantified by a chemiluminescent assay, and values were expressed in pg/ml.
of rbIFN-λ used in the previous experiment. A colorimetric
assay was used, and the percentage of living cells was referred
to values of mock-treated cells. No changes in the viability of
any of these cells were observed even at the highest rbIFN-λ
concentration assayed.
Whole blood samples from the same donors were also treated
ON with 18 IU/ml of rbIFN-λ, 20 ng/ml of LPS, and a mixture
of rbIFN-λ and LPS. The following day, IL-6 and IL-10 levels
were measured in stimulated plasma. Both IL-6 and IL-10 levels
were lower in rbIFN-λ-treated PBMCs compared to LPS-treated
samples. Interestingly, detection of IL-10 was reduced when
LPS and rbIFN-λ were used together, compared to LPS alone
(Table 4).
Activity of rbIFN-λ Against SARS-CoV-2
Activity of rbIFN-λ against SARS-CoV-2 was assessed in three
independent experiments using samples run in quadruplicates.
VERO cells were incubated ON with rbIFN-λ, human rIFN-α,
or rIFN-β and infected with an Argentinean isolate of SARS-
CoV-2. Mock-infected cells and IFN-treated non-infected wells
were used as controls. Cultures were examined for CPE at 24 h
and 48 h, when supernatants were recovered for quantitation of
SARS-CoV-2 genome copies, and cells were fixed and stained for
colorimetric assessment.
Incubation with rbIFN-λ did not produce any adverse effect in
VERO cells even at the highest concentration (18 IU/ml). On the
contrary, incubation with high concentrations of human rIFN-
α and rIFN-β was toxic for the cells in culture. About 60% of the
cells were killed by rhIFN-α and 25%were killed by rhIFN-β used
at a concentration of 9 IU/ml (Figures 3B,C).
As shown in Figure 3A, the rbIFN-λ had a strong antiviral
activity against SARS-CoV-2. The estimation of rbIFN-λ IC50
with the colorimetric assay was 0.045 IU/ml, 53 times lower than
that of human IFN-α and almost 33 times lower than rhIFN-β.
These results were consistent with CPE observation (Figure 3
and Supplementary File 3).
RT-qPCR results also showed that all the concentrations of the
rbIFN-λ tested caused a reduction of viral RNA copy number that
was significant with respect to untreated infected cells (p < 0.01;
Figure 4). Moreover, viral genome copy numbers were drastically
reduced by 2 log10 units of magnitude at a concentration of
0.1 IU/ml and were almost undetectable by the assay at higher
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FIGURE 3 | Antiviral activity of bovine rIFN-λ in VERO cells infected with SARS-CoV-2. VERO cells were treated with serial dilutions of bovine rIFN-λ (A), human
rIFN-α (B), or human rIFN-β (C). After an ON incubation, cells were infected with SARS-CoV-2 (MOI = 0.5) and incubated for 48 h, when cytopathic effect was
detected in untreated cells. Antiviral activity was estimated by staining the cell monolayers with crystal violet and reading the resulting OD at 575 nm. Percentage of
protection was referred to values of mock-treated and infected cells. Toxicity controls were run in parallel in every experiment on treated uninfected cells. The inhibitory
concentration 50% (IC50, concentration required to inhibit SARS-CoV-2 infection in 50% of the replicates analyzed) is indicated in each chart. Shaded areas depict the
toxic concentration range, defined as the concentration of IFN that induces a loss of viability in uninfected cells (a cytopathic-like effect is observed microscopically in
IFN-treated but not infected wells, with an increasing number of dead cells, which is related to the low-OD 575-nm values).
concentrations of rbIFN-λ (Figure 4A). The incubation with
rbIFN-λ at concentrations as low as 0.02 IU/ml reduced the
yield of viral RNA produced by mock-treated infected cells to
< 10% (Figure 4B). We estimated that 0.008 IU/ml of rbIFN-λ
might reduce the copy number of genomic viral RNA produced
by untreated infected cells by 50%. These results demonstrate
that rbIFN-λ is a potent inhibitor of the SARS-CoV-2 clinical
Argentinean isolate.
DISCUSSION
Administration of IFNs can be used for prophylaxis and early
therapy of COVID-19 compensating the weak IFN response
in the first stages of human SARS-CoV-2 infection (38, 39).
IFN-λ has several advantages compared to type-I IFNs and is
already under clinical trials (40). In this study, we assessed the
efficacy of a recombinant bovine IFN-λ against SARS-CoV-2.
We confirmed the in vitro safety and enhanced efficacy of
this IFN preventing SARS-CoV-2 infection in VERO cells
at concentrations significantly lower than those required for
recombinant human IFN-α and -β. To the best of our knowledge,
this is the first time a bovine IFN has been proposed as a
human biotherapeutic.
The use of bovine IFN-λ for human use is supported by
its capability of activating the human Mx promoter (28); its
high similarity with human IFN-λ1, 2, and 3; and a predicted
higher affinity for the human IFNLR1/IL10Rβ heterodimeric
receptor, at least in terms of free energy and dissociation
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FIGURE 4 | Detection of SARS-CoV-2 genome. VERO cells were infected with serial dilutions of bovine rIFN-λ and SARS-CoV-2 RNA from culture supernatant
samples and were quantified by qRT-PCR. Results are expressed as viral RNA copy number per milliliter (A) and percentage of relative viral RNA from mock-treated
and infected cells (B). Mean values ± SD from quadruplicate samples are depicted for each rbIFN-λ dilution. **Values significantly lower than those measured in the
mock-treated and infected cells (p < 0.01).
constant. It is important to consider that due to the limited
available crystallized structures, we modeled the rbIFN-λ using
the human IFN-λ/IFNLR complex as template. Even though
there are high similarities in the linear amino acid alignment,
the predictive modeling is limited by the backbone conformation
of the template and adjustments of side-chain stereochemistry-
based differences with the model, possibly concealing real
structural differences between the human and bovine proteins.
Notwithstanding these limitations, our in silico analysis revealed
that the enhanced affinity was mainly related to discrete amino
acid substitutions. Interestingly, some of these positions had
been mutagenized before to obtain a stable interaction for the
crystallographic structure assessment (25). These observations
support the idea that affinity of human IFN-λ for its receptor
may be improved and that a heterologous IFN-λ (such as
this rbIFN-λ) could have a better affinity for the human
IFNLR. Improving IFN-λ affinity might increase the downstream
signaling and improve the activation of the ISGs, reducing the
effective dose needed for therapeutic use.
Safety of the rbIFN-λ in human immune cells was confirmed
by using different viability assays. An ON incubation of rbIFN-λ
in doses as high as 18 IU/ml with human PBMCs did not affect
metabolic activity, viability, size, or granularity of these cells.
No cytotoxicity signs were found for VERO cells even at higher
concentrations than those that killed these cells when treated with
recombinant human IFN-α and -β.
The rbIFN-λ induced a cytokine pattern on human PBMCs
similar to that reported for human IFN-λ, upregulating IL-6 and
inducing low levels of IL-10 (41), thus confirming a comparable
immune activity of rbIFN-λ in human immune cells. This
cytokine profile is expected to activate the innate immunity at
the site of viral infection and promote the development of the
acquired immunity. Our results show that the co-treatment of
PBMCs with rbIFN-λ and LPS reduced IL-10 levels compared
to LPS alone, which can modulate inflammation produced by
bacterial infections (42, 43). The limited proinflammatory effect
is one of the most relevant advantages of IFN-λ compared to type
1 IFNs (44), particularly for treating COVID-19, as inflammation
has been associated with the development of severe disease.
However, the direct effect of IFN-λ on COVID-19 progression
remains unclear and the responsiveness of human immune cells
to IFN-λ is still being analyzed (22). In this scenario and with
IFN-λ being quite recently discovered (45, 46), more work is
needed to elucidate the role of this cytokine and the timing of its
application to prevent or reduce the progression of COVID-19.
Several studies show that type I and type III IFNs are effective
in reducing SARS-CoV-2 replication in VERO cells (18, 19, 47).
Lokugamage et al. recently demonstrated that a pretreatment
of VERO cells with 1,000 IU/ml of human IFN-α caused a 2-log10
drop in viral titer at 48 dpi as compared to control untreated cells
(47). We found the same result but using 0.14 IU/ml of rbIFN-λ.
Another study from Mantlo et al. (19) estimated the IC50 of
IFN-α and IFN-β treatment of VERO cells before SARS-CoV-2
infection to be 1.35 IU/ml and 0.76 IU/ml, respectively. These
values are similar to those estimated here for type I human IFNs
and over 30 times higher than the one computed in this study for
the rbIFN-λ. Although comparisons are difficult due to the use
of different IFN-quantitation methods and the various readouts
used for the infection assessments, bovine IFN-λ seems to be
more efficient than human type I IFNs to prevent SARS-CoV-2
infection in vitro.
Felgenhauer et al. showed that 10 ng/ml of rhIFN-λ
significantly reduced SARS-CoV-2 titers in VERO cells. Using
our production method, we estimate that 1 IU corresponds to
10 ng of rbIFN-λ, meaning that 0.17 ng of our rbIFN-λ (0.0175
IU/ml) would be sufficient to reducing SARS-CoV-2 replication
in VERO cells. These results suggest that about 50 times lower
concentrations of bovine IFN-λ are required to achieve a similar
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reduction rate than that achieved by human IFN-λ (18). These
estimations will be confirmed by a side-by-side assay using
recombinant human IFN-λ in future experiments.
Our results demonstrate that rbIFN-λ is more efficient than
two recombinant human type I (α- and β-) IFNs in impeding
SARS-CoV-2 infection in VERO cells. This evidence, together
with its low in vitro toxicity, the biological functions of the type
III IFNs, its high-sequence identity with human counterparts,
and its predicted enhanced binding capacity to the human
IFNLR, supports further evaluations of the rbIFN-λ as a potential
biotherapeutic compound for COVID-19 that could be produced
at affordable costs. Moreover, this strategy could be tested against
other respiratory viral infections that may emerge.
We have already proved the versatility of producing active
rbIFN-λ in HEK-293 cells, Escherichia coli, or by using a
recombinant baculovirus in insect cells (data not shown).
We envision a formulation that can be administered locally
through an inhaler (puffer) or using a nebulizer either early
after infection or as a preventive measure, two options that
have been successfully applied for human IFNs (39). A simple
administration method and the expected low cost of this antiviral
are paramount issues for low–middle-income countries (LMIC)
like ours, with significant percentages of the population with
limited access to health services and lacking even basic healthcare
needs. These therapeutic alternatives may also be relevant in a
middle-term scenario for LMIC where COVID-19 vaccines will
be available on limited grounds and firstly used in the high-risk
population, reinforcing the need for a low-cost therapeutic to
counteract future waves of SARS-CoV-2 infection.
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